EpiPen Maker Mylan to Explore Options, Shares Sink

Drugmaker Mylan NV (MYL) said Wednesday, Aug. 8, that its board is "actively evaluating" alternatives.

The news release did not specify the options being explored. The board has not set a timeframe for the strategic review.

"[W]e believe that the US public markets continue to underappreciate and undervalue the durability, differentiation and strengths of Mylan's global diversified business, especially when compared to our peers around the globe," the board said.

The announcement comes as Mylan unveiled second-quarter numbers. The company reported adjusted diluted EPS of $1.07, down 3% from the year-ago period. Revenue declined 5% to $2.81 billion.

Analysts had forecast, on average, adjusted EPS of $1.22 on revenue of $2.96 billion, according to Bloomberg.

Shares of Mylan were trading at $37.20 ahead of the open on Wednesday, down 3.5%.

More from Mergers and Acquisitions

These 3 Marijuana-Related Stocks Are Ripe for Takeover

These 3 Marijuana-Related Stocks Are Ripe for Takeover

Tech M&A Actions Shows No Signs of Abating

Tech M&A Actions Shows No Signs of Abating

Slogging Through the Deep-Value Valley With Valhi and NL Industries in Tow

Slogging Through the Deep-Value Valley With Valhi and NL Industries in Tow

IBM Sells Software Portfolio to India's HCL Technologies

IBM Sells Software Portfolio to India's HCL Technologies

Euromoney Buys The Deal, BoardEx

Euromoney Buys The Deal, BoardEx